What's in Seng Gee Lim's pipeline?

Seng Gee Lim has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Seng Gee Lim's portfolio?

Top competitors by shared drug class: King Abdullah International Medical Research Center.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/seng-gee-lim.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Seng Gee Lim — Portfolio Competitive Intelligence Brief

Seng Gee Lim pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Nucleos(t)ide analogue therapy	Nucleos(t)ide analogue therapy	marketed	Nucleos(t)ide reverse transcriptase inhibitor / Nucleos(t)ide polymerase inhibitor	Viral reverse transcriptase (HIV) or viral polymerase (HBV)	Virology / Infectious Disease

Therapeutic area mix

Virology / Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

King Abdullah International Medical Research Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Seng Gee Lim:

Cite this brief

Drug Landscape (2026). Seng Gee Lim — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/seng-gee-lim. Accessed 2026-05-15.